Relay Therapeutics (RLAY) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Relay Therapeutics (RLAY) has outperformed Vericel (VCEL) over the past year, gaining 138.1% versus a gain of 45.3%. Over five years, VCEL leads with a +50.1% price change compared with -45.9% for RLAY. Relay Therapeutics is the larger company by market cap ($3.56 billion vs $2.94 billion), about 1.2 times the size.
Vericel converts more of its revenue into profit, with a net margin of 6.0% versus -1800.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RLAY | VCEL |
|---|---|---|
| Share price | $16.12 | $57.52 |
| Market cap | $3.56B | $2.94B |
| 1-day change | +1.32% | -1.27% |
| YTD return | +90.54% | +59.73% |
| 1-year return | +138.11% | +45.33% |
| 5-year return | -45.92% | +50.14% |
| P/E ratio (TTM) | — | 89.88 |
| Forward P/E | — | 61.06 |
| EPS (TTM) | $-1.50 | $0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $15.36M | $276.26M |
| Revenue growth (YoY) | +53.44% | +16.45% |
| Net income (latest FY) | $-276.48M | $16.52M |
| Gross margin | — | 74.42% |
| Operating margin | -1971.59% | 4.00% |
| Net margin | -1800.58% | 5.98% |
| 52-week high | $21.27 | $59.75 |
| 52-week low | $6.80 | $28.95 |
| Distance from 52-week high | -24.21% | -3.73% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +75.25% | +13.75% |
| Average volume | 2.93M | 664.34K |
| Shares outstanding | 220.96M | 51.03M |
| Employees | 218 | 398 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLAY has outperformed VCEL by 92.8 percentage points over the past year.
- Vericel is more profitable, keeping 6.0 cents of every revenue dollar as net income versus -1800.6 cents for Relay Therapeutics.
- Relay Therapeutics grew revenue faster in its latest fiscal year (+53.44% vs +16.45%).
About Relay Therapeutics
RLAY stock →Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 218 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees
RLAY vs VCEL FAQ
Which is bigger, Relay Therapeutics or Vericel?
Relay Therapeutics (RLAY) is larger, with a market capitalization of $3.56B compared with $2.94B for Vericel (VCEL).
Which stock has performed better over the past year, RLAY or VCEL?
RLAY returned +138.11% over the past 12 months, compared with +45.33% for VCEL (price return, excluding dividends). Past performance does not predict future results.
Are Relay Therapeutics and Vericel in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.